Advertisement
News
Advertisement

ACT stem cell trial in U.S. shows signs of safety

Tue, 01/24/2012 - 9:48pm
Mass High Tech: The Journal of New England Technology

Advanced Cell Technology Inc. (ACT) today released data from a U.S. clinical trial testing the safety of treating Stargardt’s macular dystrophy (SMD) with human embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) cells. The news comes one day after the Marlborough company announced that it had started using its hESC on an SMD patient in a Phase 1/2 trial in Europe.

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading